Detalhe da pesquisa
1.
Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety.
Hematol Oncol
; 42(1): e3222, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37740931
2.
Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis.
Br J Clin Pharmacol
; 90(3): 748-758, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855131
3.
Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.
Eur J Clin Pharmacol
; 75(2): 207-216, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30291369
4.
Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials.
Hematol Oncol
; 2018 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29672885
5.
Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.
Xenobiotica
; 48(9): 904-910, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29027832
6.
Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.
J Pharmacokinet Pharmacodyn
; 45(3): 443-456, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29427135
7.
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Hematol Oncol
; 35(4): 679-684, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27982454
8.
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
Br J Clin Pharmacol
; 83(3): 527-539, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27662429
9.
Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
Antimicrob Agents Chemother
; 60(2): 855-61, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26596948
10.
Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.
Antimicrob Agents Chemother
; 60(1): 105-14, 2016 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26459906
11.
Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Ther Drug Monit
; 38(5): 640-5, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27310199
12.
Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
J Hepatol
; 63(4): 805-12, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26070406
13.
Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
J Hepatol
; 63(1): 20-9, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25646891
14.
Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor.
Clin Transl Sci
; 17(5): e13807, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38778732
15.
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study.
Cancer Chemother Pharmacol
; 93(4): 329-339, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38036720
16.
Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis.
J Clin Pharmacol
; 63(1): 119-125, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35996877
17.
Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature.
J Vasc Surg
; 55(2): 400-5, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22051872
18.
Effects of a ritonavir-containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects.
Pharmacol Res Perspect
; 10(6): e01024, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36416673
19.
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.
Cancer Chemother Pharmacol
; 87(4): 465-474, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33398386
20.
Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers.
Mol Cancer Ther
; 20(6): 999-1008, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33785651